Zefen Xiao

List of Publications by Citations

74	902	17	27
papers	citations	h-index	g-index
82	1,206	3.8	3.57
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
74	Primary small cell carcinoma of the esophagus. *Journal of Thoracic Oncology*, **2008**, 3, 1460-5	8.9	70
73	Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. *Radiotherapy and Oncology*, **2010**, 97, 488-94	5.3	62
72	Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. *Oncologist*, **2011**, 16, 641-50	5.7	55
71	Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. *Oncogene*, **2019**, 38, 4990-5006	9.2	43
70	Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. *Annals of Thoracic Surgery*, **2014**, 98, 513-9	2.7	39
69	PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. *Cancer Research*, **2009**, 69, 3283-90	10.1	39
68	Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 330-7	4	36
67	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. *OncoTargets and Therapy*, **2017**, 10, 763-771	4.4	34
66	Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma. *World Journal of Surgical Oncology*, **2013**, 11, 278	3.4	30
65	Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage III thoracic esophageal squamous cell carcinoma. *Oncology Research and Treatment*, **2015**, 38, 97-102	2.8	28
64	High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. *Tumor Biology*, **2011**, 32, 1147-53	2.9	28
63	Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. *Cancer Science*, **2017**, 108, 590-597	6.9	27
62	The Impact of Postoperative Conformal Radiotherapy after Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis. *Journal of Thoracic Oncology*, **2017**, 12, 1143-1151	8.9	23
61	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 1178-1185	13.4	23
60	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. *Oncologist*, **2016**, 21, 1530-1537	5.7	22
59	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2016**, 11, 1565-73	8.9	20
58	Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. *Thoracic Cancer*, **2015**, 6, 346-53	3.2	17

57	Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. *Translational Oncology*, **2018**, 11, 999-1006	4.9	16
56	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. *Thoracic Cancer*, **2015**, 6, 399-406	3.2	16
55	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. *Annals of Thoracic Surgery*, **2017**, 104, 1718-1724	2.7	15
54	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. *Radiation Oncology*, **2019**, 14, 48	4.2	15
53	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. *Annals of Surgical Oncology*, **2019**, 26, 2890-2898	3.1	14
52	Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. *Thoracic Cancer*, **2015**, 6, 597-604	3.2	14
51	Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. *Oncologist*, **2020**, 25, e701-e708	5.7	11
50	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. *Oncotarget*, **2016**, 7, 55211-55221	3.3	11
49	Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. *BMC Cancer*, **2019**, 19, 478	4.8	10
48	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. *Radiation Oncology*, **2019**, 14, 106	4.2	10
47	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. *BMC Cancer*, **2019**, 19, 397	4.8	10
46	Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis. *OncoTargets and Therapy*, **2018**, 11, 3087-3100	4.4	10
45	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. *Radiotherapy and Oncology*, **2019**, 140, 159-166	5.3	10
44	Small proline-rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage-induced apoptosis. *Molecular Oncology*, **2013**, 7, 955-67	7.9	10
43	Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. *Radiation Oncology*, **2015**, 10, 142	4.2	10
42	Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer. *Annals of Thoracic Surgery*, **2019**, 108, 1701-1709	2.7	9
41	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. *Thoracic Cancer*, **2019**, 10, 1431-1440	3.2	9
40	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. *BMC Cancer*, **2020**, 20, 144	4.8	8

39	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. *Oncotarget*, **2017**, 8, 41102-41112	3.3	8
38	Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A). *BMC Cancer*, **2020**, 20, 36	4.8	7
37	Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems. *Thoracic Cancer*, **2014**, 5, 204-10	3.2	7
36	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. *JAMA Network Open*, **2019**, 2, e1918070	10.4	7
35	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. *Journal of Cancer*, **2019**, 10, 1985-1990	4.5	6
34	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). *Oncotarget*, **2017**, 8, 48922-48929	3.3	6
33	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. *BMC Cancer*, **2020**, 20, 130	4.8	5
32	Associations of ATM Polymorphisms With Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Receiving Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2015**, 93, 181-9	4	4
31	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. *Frontiers in Oncology*, **2020**, 10, 1499	5.3	4
30	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. *Acta Oncologica*, **2021**, 60, 627-634	3.2	4
29	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 814-823	3.2	4
28	Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma. *Scientific Reports*, **2019**, 9, 10497	4.9	3
27	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. *Radiotherapy and Oncology*, **2021**, 156, 244-250	5.3	3
26	Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study. *Frontiers in Oncology*, **2020**, 10, 580450	5.3	2
25	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. *BMC Cancer*, **2020**, 20, 901	4.8	2
24	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. *Radiation Oncology*, **2021**, 16, 102	4.2	2
23	RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. *Future Oncology*, **2021**, 17, 4081-4089	3.6	2
22	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. *Thoracic Cancer*, **2019**, 10, 799-806	3.2	2

21	Small cell lung cancer in the young: Characteristics, diagnosis and outcome data. *Clinical Respiratory Journal*, **2019**, 13, 98-104	1.7	2
20	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. *BMC Cancer*, **2020**, 20, 278	4.8	2
19	Prognosis of R1-resection at the bronchial stump in patients with non-small cell lung cancer. *Chinese Medical Journal*, **2014**, 127, 2918-23	2.9	2
18	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.. *Thoracic Cancer*, **2021**,	3.2	2
17	Radiotherapy for carcinoma of the Esophagus: Progress of treatment and research in China. *Chinese Journal of Clinical Oncology*, **2006**, 3, 305-314		1
16	Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). *Annals of Translational Medicine*, **2020**, 8, 1140	3.2	1
15	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. *BMC Cancer*, **2020**, 20, 877	4.8	1
14	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. *Thoracic Cancer*, **2021**, 12, 1831-1840	3.2	1
13	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. *Lung Cancer*, **2021**, 157, 116-123	5.9	1
12	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. *Oncologist*, **2021**, 26, e2151-e2160	5.7	1
11	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution.. *Annals of Surgical Oncology*, **2022**, 1	3.1	1
10	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis.. *Frontiers in Oncology*, **2021**, 11, 781340	5.3	0
9	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy.. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211061948	5.4	0
8	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. *Tumori*, **2021**, 107, 407-415	1.7	0
7	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. *Annals of Surgical Oncology*, **2021**, 28, 7076-7086	3.1	0
6	Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A).. *Translational Cancer Research*, **2021**, 10, 2932-2943	0.3	0
5	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. *Clinical Medicine Insights: Oncology*, **2022**, 16, 11795549221080347	1.8	0
4	ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy. *Annals of Surgical Oncology*, **2019**, 26, 802-803	3.1	

3	A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC).. *Journal of Clinical Oncology*, **2020**, 38, TPS475-TPS475	2.2
2	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. *Frontiers in Oncology*, **2021**, 11, 618776	5.3
1	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma.. *Radiation Oncology*, **2022**, 17, 58	4.2